1
Home
Companies

Concert Pharmaceuticals

Concert Pharmaceuticals
Leadership team

Mr. Richard H. Aldrich M.B.A., Mba (Co-Founder & Independent Chairman)

Dr. Roger D. Tung Ph.D. (Co-Founder, CEO, Pres & Exec. Director)

Mr. Marc A. Becker (Chief Financial Officer)

Products/ Services
Biotechnology, Health Care, Medical
Number of Employees
50 - 100
Headquarters
Lexington, Massachusetts, United States
Established
2006
Company Registration
SEC CIK number: 0001367920
Traded as
CNCE
Social Media
URL
https://www.concertpharma.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
History

Concert Pharmaceuticals was founded in 2006 under the leadership of Roger Tung, Ph.D., biopharmaceutical veteran. The company has developed a proprietary platform to identify and develop novel small molecule drugs by utilizing advanced DMPK, medicinal and computational chemistry, and optimizes drug development candidates for improved safety, efficacy and dosing relative to marketed drugs.

Mission
Concert Pharmaceuticals’ mission is to use its proprietary deuterated chemical entity (DCE) platform to discover, develop and bring to market innovative drugs that provide meaningful therapeutic benefit to patients.
Vision
Concert Pharmaceuticals believes in a vision of a world in which patients experience meaningful therapeutic benefit from its medicines.
Key Team

Ms. Nancy Stuart (Chief Operating Officer)

Ms. Justine E. Koenigsberg (Sr. VP of Corp. Communications & Investor Relations)

Mr. Jeffrey A. Munsie (Chief Legal Officer & Corp. Sec.)

Dr. Nabil Uddin Pharm.D. (VP of Corp. Devel.)

Ms. Christine Boisclair (Sr. VP of Regulatory Affairs & Quality Assurance)

Dr. James V. Cassella Ph.D. (Chief Devel. Officer)

Recognition and Awards
Concert Pharmaceuticals has been recognized by the Massachusetts Life Sciences Center with the MassMedic Life Science Innovation Award and the 2018 RISN New England Public Company of the Year. In addition, Concert Pharmaceuticals has received several prestigious awards including the 2016 Frost & Sullivan New Product Innovation Award, the 2015 Design of Experiments Leadership Award, and the 2015 Gene Design Award.
References

https://in.investing.com/equities/concert-pha

https://finance.yahoo.com/quote/CNCE/profile?p=CNCE

https://www.crunchbase.com/organization/concert-pharmaceuticals

https://companiesmarketcap.com/

https://www.concertpharma.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Concert Pharmaceuticals
Leadership team

Mr. Richard H. Aldrich M.B.A., Mba (Co-Founder & Independent Chairman)

Dr. Roger D. Tung Ph.D. (Co-Founder, CEO, Pres & Exec. Director)

Mr. Marc A. Becker (Chief Financial Officer)

Products/ Services
Biotechnology, Health Care, Medical
Number of Employees
50 - 100
Headquarters
Lexington, Massachusetts, United States
Established
2006
Company Registration
SEC CIK number: 0001367920
Traded as
CNCE
Social Media
URL
https://www.concertpharma.com